Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hormel Foods Corp (HRL) vs Novartis AG (NVS) Price & Performance

Hormel Foods CorpTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Hormel Foods Corp vs Novartis AG — how do they compare? Hormel Foods Corp trades at $24.18 (market cap $13.37B), while Novartis AG trades at $152.32 (market cap $295.37B). The key difference: Novartis AG is far larger — about 22.1× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.81%). Which is the better fit depends on your goals.

HRLNVS
Market Cap
$13.37B$295.37B
Sector
Consumer StaplesHealth
52-Week High
$29.25$168.62
52-Week Low
$19.74$119.31
Enterprise Value
$15.37B$336.69B
Dividend Yield
4.81%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hormel Foods Corp

Hormel Foods (HRL) trades at $24.705, down 1.26% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.40, beating expectations, but net income margin declined to 3.82% in 2025. Recent news includes the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.

Outlook is mixed: strong dividend yield and consistent earnings beats support income investors, but margin pressures and bearish technicals pose near-term risks. Analyst consensus is 'Hold' with a $26.33 price target, suggesting limited upside. Macroeconomic headwinds in consumer staples may challenge growth.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hormel Foods Corp

Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.

Read more on HRL

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS